Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA

Financing and Distribution of Pharmaceuticals in the United States

(2017) Matan C. Dabora et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending

(2017) Stacie B. Dusetzina et al.   JAMA Internal Medicine

Stemming the Escalating Cost of Prescription Drugs: A Position Paper of the American College of Physicians

(2016) Hilary Daniel et al.   ANNALS OF INTERNAL MEDICINE

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

(2016) Peter Alping et al.   ANNALS OF NEUROLOGY

Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States

(2016) Aseel Bin Sawad et al.   CURRENT MEDICAL RESEARCH AND OPINION

Reducing costs while enhancing quality of care in MS: Table

(2016) Ilya Kister et al.   NEUROLOGY

Multiple sclerosis prevalence in the United States commercially insured population

(2016) Piyameth Dilokthornsakul et al.   NEUROLOGY

State Initiatives to Control Medication Costs — Can Transparency Legislation Help?

(2016) Ameet Sarpatwari et al.   NEW ENGLAND JOURNAL OF MEDICINE

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

(2015) D. M. Hartung et al.   NEUROLOGY

Medicare payments to the neurology workforce in 2012

(2015) L. E. Skolarus et al.   NEUROLOGY

The Patient Protection and Affordable Care Act and Chronic Neurological Illnesses

(2015) Gregory J. Esper et al.   JAMA Neurology

Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis

(2015) Dennis Bourdette et al.   JAMA Neurology

Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010

(2014) MerriKay Oleen-Burkey et al.   BMC Neurology

Drug Companies' Patient-Assistance Programs — Helping Patients or Profits?

(2014) David H. Howard   NEW ENGLAND JOURNAL OF MEDICINE

Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

(2014) Peter J. Neumann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prescription-Drug Coupons — No Such Thing as a Free Lunch

(2013) Joseph S. Ross et al.   NEW ENGLAND JOURNAL OF MEDICINE

The cost burden of multiple sclerosis in the United States: a systematic review of the literature

(2013) Gabriel Adelman et al.   JOURNAL OF MEDICAL ECONOMICS

Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis

(2013) Annie Hawton et al.   Applied Health Economics and Health Policy

Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US

(2012) J. I. Ivanova et al.   JOURNAL OF MEDICAL ECONOMICS

Immune mechanisms of new therapeutic strategies in MS — Teriflunomide

(2011) Malte C. Claussen et al.   CLINICAL IMMUNOLOGY

Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A population-based study

(2011) K. Noyes et al.   NEUROLOGY

Impact of Adherence to Interferons in the Treatment of Multiple Sclerosis

(2010) Stephanie C. Steinberg et al.   CLINICAL DRUG INVESTIGATION

The changing demographic pattern of multiple sclerosis epidemiology

(2010) Nils Koch-Henriksen et al.   LANCET NEUROLOGY

What Is Value in Health Care?

(2010) Michael E. Porter   NEW ENGLAND JOURNAL OF MEDICINE

The Cost of Disability and Medically Related Absenteeism Among Employees with Multiple Sclerosis in the US

(2010) Jasmina I. Ivanova et al.   PHARMACOECONOMICS

Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs

(2010) Matthew W. Reynolds et al.   JOURNAL OF MEDICAL ECONOMICS

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE